BPC-157 is often labeled with disclaimers such as Not for human consumption or For research purposes only, and is not listed in the FDAs Approved Drugs database
Where most therapeutic peptides degrade within minutes under simulated gastric or intestinal conditions, BPC-157 retains its integrity in human gastric juice for more than 24 hours, tolerates a wide pH range, and resists multiple proteolytic enzymes including pepsin and trypsin
However, subcutaneous injection remains the most reliable administration route for consistent dosing
Recovery from exercise and physical stress improves within 2-3 weeks
Malignant pleural and pericardial effusions in breast cancer
(Li et al., 2020) found that the mean uterine volume decreased from 44.9 17.8 cm 3 prior to menopause, to 16.3 10.6 cm 3 after menopause